BCL2 and cholangiocarcinoma: Another drug that promotes Beclin1 activation is pristimerin, which inhibited CCA cell growth in vitro and in vivo, decreasing apoptosis-related proteins Bcl-2, Bcl-XL and procaspase-3, similar to the effect of BH3 mimetics, suggesting pristimerin promotes Beclin1 activation and initiation of autophagy.